It wants to get ahead of competitors such as BMS, Merck, Pfizer ... The interaction with GSK goes deeper, with Novartis and GSK announcing a merger of their OTC divisions to create a new joint ...

Pfizer and GSK plan to divest the business completely ... and the deal was instantly controversial in both Europe and the US. The merger would have created the biggest pharmaceutical company ...

The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.

Parke-Davis (India) in the near future is unlikely to get five major products which Glaxo Wellcome worldwide ... The operational merger between Pfizer and Parke-Davis has been completed and ...

A total of 739 deals were completed so far this year representing a decrease of just under 21 per cent compared to last year.

GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer (PFE). The departures coincided with a drop in lobbying spending from the group and other challenges, STAT says.

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

Nov 5 (Reuters) - GSK (GSK.L), opens new tab has received ... It was previously approved only for those 60 and older in Canada, as is Pfizer's (PFE.N), opens new tab RSV vaccine, Abrysvo.

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...